Application of PK-PD Modeling in Understanding Bystander Effect for Antibody Drug Conjugates

被引：0
|
作者：
Singh, Aman P. [1 ]
Shah, Dhaval K. [1 ]
机构：
[1] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Buffalo, NY USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2017年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
M-041
引用
收藏
页码：S27 / S28
页数：2
相关论文
共 50 条
  • [21] Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research
    Danhof, Meindert
    de Lange, Elizabeth C. M.
    Della Pasqua, Oscar E.
    Ploeger, Bart A.
    Voskuyl, Rob A.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2008, 29 (04) : 186 - 191
  • [22] Integrated PK-PD and agent-based modeling in oncology
    Zhihui Wang
    Joseph D. Butner
    Vittorio Cristini
    Thomas S. Deisboeck
    Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42 : 179 - 189
  • [23] PK-PD modeling of β-lactam antibiotics: In vitro or in vivo models?
    de Araujo, Bibiana Verlindo
    Diniz, Andrea
    Palma, Eduardo Celia
    Buffe, Candida
    Costa, Teresa Dalla
    JOURNAL OF ANTIBIOTICS, 2011, 64 (06): : 439 - 446
  • [24] Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin
    Betts, Alison M.
    Haddish-Berhane, Nahor
    Tolsma, John
    Jasper, Paul
    King, Lindsay E.
    Sun, Yongliang
    Chakrapani, Subramanyam
    Shor, Boris
    Boni, Joseph
    Johnson, Theodore R.
    AAPS JOURNAL, 2016, 18 (05): : 1101 - 1116
  • [25] Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin
    Alison M. Betts
    Nahor Haddish-Berhane
    John Tolsma
    Paul Jasper
    Lindsay E. King
    Yongliang Sun
    Subramanyam Chakrapani
    Boris Shor
    Joseph Boni
    Theodore R. Johnson
    The AAPS Journal, 2016, 18 : 1101 - 1116
  • [26] PK-PD modeling of protein drugs: implications in assay development
    Roskos, Lorin K.
    Schneider, Amy
    Vainshtein, Inna
    Schwickart, Martin
    Lee, Rozanne
    Lu, Hong
    Faggioni, Raffaella
    Liang, Meina
    BIOANALYSIS, 2011, 3 (06) : 659 - 675
  • [27] Integrated PK-PD and agent-based modeling in oncology
    Wang, Zhihui
    Butner, Joseph D.
    Cristini, Vittorio
    Deisboeck, Thomas S.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 (02) : 179 - 189
  • [28] PK-PD modeling of β-lactam antibiotics: In vitro or in vivo models?
    Bibiana Verlindo de Araujo
    Andrea Diniz
    Eduardo Célia Palma
    Cândida Buffé
    Teresa Dalla Costa
    The Journal of Antibiotics, 2011, 64 : 439 - 446
  • [29] Research on the mechanism of drug–drug interaction between salvianolate injection and aspirin based on the metabolic enzyme and PK-PD model: study protocol for a PK-PD trial
    Wantong Zhang
    Baochen Zhu
    Weiyi Cao
    Rui Li
    Shuge Wang
    Rui Gao
    Trials, 19
  • [30] PK-PD modeling of ketamine in neurotraumatized intensive care patients
    Hijazi, Y
    Bodonian, C
    Salord, F
    Bressolle, F
    Boulieu, R
    THERAPEUTIC DRUG MONITORING, 2003, 25 (04) : 520 - 520
12345